|
Emisphere Technologies Incorporated - Comparative Business Analysis Snapshot
Business Description
Emisphere Technologies Incorporated. The Group's principal activity is developing product candidates for therapeutic areas, including cardiovascular disease, diabetes, osteoporosis, growth disorders, asthma and allergies, obesity and infectious diseases. It has not yet obtained the regulatory approval for sales of any of its product candidates. It has drug candidates in development stage namely, Oral Unfractionated Heparin and Oral Low Molecular Weight Heparin for Cardivascular, Oral Salmon Calcitonin and Oral Recombinant Parathyroid Hormone for Osteoporosis, Partner proprietary small molecule compounds for Bone-related diseases, Oral Recombinant Human Growth Hormone for Growth Disorders, Oral Insulin & Oral Glucagon-Like Peptides for Diabetes, Oral Cromolyn Sodium for Asthma/Allergies, Oral Ciliary Neutrophic Growth Factor and Oral PYY3-36 for Obesity and Oral Anthrax Antigen for Anti-infectives. The Group has operations in the United States.
Competitor Analysis
This analysis compares Emisphere Technologies Incorporated with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
